Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Acquires 10,000 Shares

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi bought 10,000 shares of Prelude Therapeutics stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $1.20 per share, with a total value of $12,000.00. Following the acquisition, the chief executive officer now directly owns 137,553 shares of the company's stock, valued at approximately $165,063.60. This represents a 7.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, December 18th, Krishna Vaddi purchased 100,000 shares of Prelude Therapeutics stock. The shares were acquired at an average cost of $0.93 per share, for a total transaction of $93,000.00.

Prelude Therapeutics Trading Down 2.0 %

NASDAQ PRLD traded down $0.03 on Thursday, reaching $1.25. The stock had a trading volume of 309,727 shares, compared to its average volume of 217,047. Prelude Therapeutics Incorporated has a 1 year low of $0.80 and a 1 year high of $6.80. The business has a 50 day moving average price of $1.12 and a 200 day moving average price of $3.02. The company has a market capitalization of $68.79 million, a price-to-earnings ratio of -0.70 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05. The firm had revenue of $3.00 million during the quarter. On average, analysts anticipate that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PRLD. JMP Securities reaffirmed a "market outperform" rating and set a $4.00 target price (down previously from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Prelude Therapeutics in a research note on Friday, November 8th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. increased its holdings in shares of Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company's stock valued at $362,000 after acquiring an additional 157,218 shares during the last quarter. State Street Corp boosted its position in Prelude Therapeutics by 35.1% during the third quarter. State Street Corp now owns 286,046 shares of the company's stock worth $592,000 after purchasing an additional 74,300 shares during the period. Walleye Capital LLC grew its holdings in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company's stock valued at $172,000 after purchasing an additional 67,946 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Prelude Therapeutics in the third quarter valued at approximately $100,000. Finally, Geode Capital Management LLC lifted its stake in shares of Prelude Therapeutics by 8.2% in the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company's stock worth $811,000 after buying an additional 29,765 shares during the last quarter. Institutional investors and hedge funds own 79.72% of the company's stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.